HM2-CAR-T cells exhibited a stronger cytotoxicity against CLDN18.2-AsPCP-1 cells compared to other humanized VHH CAR-T cells (Figures 3D, F), indicating HM2 was the most potent humanized VHH for engineering T cells to lyse CLDN18.2-positive tumor cells. The gene discussed is CLDN18; the disease is neoplasm.